BEIGF:OTCMKTS
BeOne Medicines
21,95 US$
0,00%
(0,00) 1 d
9 jun, 12:49:46 GMT-4 · USD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de BEIGF...
Cap. burs.
43,13 mil M
Vol. medio
0,00
Volumen
0,00
Máximo en 52 sem.
24,92 US$
Mínimo en 52 sem.
21,95 US$
Beta
0,84
Acciones en circulación
1427,23 M
N.º de empleados
12 mil
Cap. burs.
43,13 mil M
Vol. medio
0,00
Volumen
0,00
Máximo en 52 sem.
24,92 US$
Mínimo en 52 sem.
21,95 US$
Beta
0,84
Acciones en circulación
1427,23 M
N.º de empleados
12 mil
Noticias
De fuentes web y partners de noticias
TipRanks
·
hace 1 hora
BeOne Medicines Grants New RSUs to 277 Employees Under Incentive Plan
Perfil
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Acerca de BeOne Medicines
CEOJohn Vincent Oyler | John Vincent Oyler
Empleados12 mil
Fundación28 oct 2010
Sede-
Sector-
Sitio webbeonemedicines.com